David Mountcastle Sells 600 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Key Points

• Privia Health CFO David Mountcastle sold 600 shares on July 7 at an average price of $27.57, totaling $16,542. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still owned 186,128 shares afterward.
• The CFO has been actively trimming his stake, with several earlier sales in recent weeks, including a much larger sale of 24,734 shares on July 2 and 17,196 shares on June 26.
• PRVA shares rose 2.1% to $27.77, near their 52-week high of $27.81. The stock has a market cap of about $3.5 billion, and Wall Street currently rates it a Moderate Buy with an average target price of $31.15.

Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) CFO David Mountcastle sold 600 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $27.57, for a total value of $16,542.00. Following the transaction, the chief financial officer owned 186,128 shares in the company, valued at $5,131,548.96. The trade was a 0.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Thursday, July 2nd, David Mountcastle sold 24,734 shares of Privia Health Group stock. The stock was sold at an average price of $27.50, for a total transaction of $680,185.00.
• On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The shares were sold at an average price of $25.18, for a total transaction of $432,995.28.
• On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The stock was sold at an average price of $22.60, for a total value of $76,501.00.
• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $30,150.00.
• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total value of $179,690.37.

Privia Health Group Stock Up 2.1%

Shares of NASDAQ:PRVA traded up $0.56 during trading on Thursday, reaching $27.77. 1,133,894 shares of the company traded hands, compared to its average volume of 940,108. The firm has a market capitalization of $3.50 billion, a PE ratio of 173.57, a PEG ratio of 2.15 and a beta of 0.83. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $27.81. The company's 50 day moving average is $23.65 and its two-hundred day moving average is $23.08.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Bayban bought a new stake in shares of Privia Health Group during the fourth quarter worth about $26,000. Hantz Financial Services Inc. increased its stake in shares of Privia Health Group by 456.2% in the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company's stock valued at $27,000 after buying an additional 926 shares during the period. Global Retirement Partners LLC raised its holdings in Privia Health Group by 579.8% in the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company's stock valued at $38,000 after buying an additional 1,351 shares during the last quarter. Harbor Investment Advisory LLC bought a new position in Privia Health Group in the 2nd quarter valued at approximately $69,000. Finally, Canada Pension Plan Investment Board boosted its position in Privia Health Group by 48.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company's stock worth $85,000 after buying an additional 1,200 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Evercore set a $26.00 target price on shares of Privia Health Group in a report on Wednesday, April 8th. Barclays cut their price target on shares of Privia Health Group from $25.00 to $24.00 and set an "equal weight" rating for the company in a report on Tuesday, May 26th. Canaccord Genuity Group reduced their price target on shares of Privia Health Group from $35.00 to $34.00 and set a "buy" rating on the stock in a research report on Friday, May 8th. Weiss Ratings raised shares of Privia Health Group from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, July 2nd. Finally, Zacks Research downgraded shares of Privia Health Group from a "hold" rating to a "strong sell" rating in a research report on Tuesday. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.15.

Privia Health Group Company Profile

Privia Health Group NASDAQ: PRVA is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.